ClinicalTrials.gg
RecruitingNCT05439902ALPHA-SEPUpdated Jun 25, 2024

Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women

An interventional study of Tamsulosin and Placebo in Multiple Sclerosis, Dysuria and Lower Urinary Tract Symptoms, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-25.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Oct 2022; still recruiting 4 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes — 1 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · Centre Hospitalier Universitaire de Nīmes.

Started
2022
with 1 other
No phase
5 of 13
1 open now
Registered
11th of 13
by date

Among the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes, this one is one of 2 that started in 2022, is one of 5 with no phase, and was the 11th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

1 of the 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Multiple Sclerosis by Centre Hospitalier Universitaire de Nīmes, or all of them as a file.
02

Study summary

Multiple sclerosis (MS) is the leading non-traumatic cause of severe acquired disability in young people. The disease is defined by relapses, which can affect all neurological functions depending on the location of the new inflammatory lesion(s). The disease can thus manifest itself through bladder and bowel disorders (BWS), which affect approximately 80% of MS patients in all stages. Lower urinary tract dysfunction has a significant negative impact on the quality of life of patients and places a significant burden on the healthcare system in terms of resource allocation. In addition, there is a risk of long-term chronic renal failure, an infectious risk (recurrent cystitis and/or pyelonephritis, sometimes life-threatening) and a lithiasis risk.

The most frequently observed urinary symptoms are: urinary frequency, urgency with or without urinary incontinence, dysuria and chronic retention of urine. These disorders most often combine bladder hyperactivity and dysuria. This dysuria may be responsible for recurrent urinary tract infections, lithiasis, alteration of renal function.

The only therapeutic class currently used to treat dysuria in MS is alpha-blockers. Tamsulosin, alfusozin and doxazosin induce relaxation of the urethral smooth sphincter and prostatic urethral muscle fibers, facilitating the removal of subvesical obstruction and bladder emptying.

The study investigators hypothesize that treatment with tamsulosin 0.4 mg daily in adult MS patients with dysuria will result in symptom improvement as assessed by the International Prostate Symptom Score (IPSS) and Urinary Symptom Profile (USP) scores, a decrease in post-void residual, and an improvement in urine flow and quality of life.

03

Conditions studied

  • Multiple Sclerosis
  • Dysuria
  • Lower Urinary Tract Symptoms
  • Voiding Dysfunction
  • Urinary Retention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient must have given their free and and signed the consent form
  • The patient must be a member or beneficiary of a health insurance plan
  • Patient with multiple sclerosis (EDSS score \< 7.5).
  • Moderate to severe dysuria (IPSS score > 7) due to bladder sphincter dyssynergia confirmed by complete urodynamic workup.
  • Patient under stable treatment.

Exclusion criteria

Exclusion Criteria:

  • The subject is participating in another category 1 interventional study, or a trial involving a non-CE marked or CE marked off-label medical device or is in a period of exclusion determined by a previous study
  • The subject refuses to sign the consent
  • It is impossible to give the subject informed information
  • The patient is under safeguard of justice or state guardianship
  • to tamsulosin hydrochloride, including angioedema induced by the drug or any of the .
  • History of orthostatic hypotension.
  • Severe hepatic impairment.
  • Concomitant treatment with diclofenac, warfarin, inhibitors.
    • Patient with complete urinary retention at the time of the pre-inclusion consultation, requiring management by intermittent self-catheterization or, failing that, an indwelling bladder catheter from the outset.
  • Major medical or psychiatric illness that, in the opinion of the investigator, would place the subject at risk or could compromise compliance with the study protocol.
  • Presence of another neurological pathology (excluding MS).
  • Swallowing problems that compromise oral medication.
  • Scheduled cataract surgery within 4 months.
  • Pregnant, parturient or breastfeeding patient.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Tamsulosin

    Drug: Tamsulosin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • One 0.4mg Tamsulosin capsule taken per day for 30 days

  • DrugPlacebo

    one placebo capsule per day for 30 days. with identical appearance (color and size) to the experimental drug, composed of microcrystalline cellulose

06

What researchers measure

Primary outcomes

  1. Urinary symptoms between groups

    Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35

    Time frame: Start of first intervention phase (Day 0)

  2. Urinary symptoms between groups

    Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35

    Time frame: End of first intervention phase (Day 30)

  3. Urinary symptoms between groups

    Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35

    Time frame: Start of first intervention phase (Day 60)

  4. Urinary symptoms between groups

    Measured using the International Prostate Symptom Scale (IPSS), scoring ranging from 0-35

    Time frame: End of first intervention phase (Day 90)

Secondary outcomes

  1. Urinary symptoms between groups

    Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39

    Time frame: Start of first intervention phase (Day 0)

  2. Urinary symptoms between groups

    Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39

    Time frame: End of first intervention phase (Day 30)

  3. Urinary symptoms between groups

    Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39

    Time frame: Start of first intervention phase (Day 60)

  4. Urinary symptoms between groups

    Measured using the Urinary Symptom Profile (USP) questionnaire: score ranging from 0-39

    Time frame: End of first intervention phase (Day 90)

  5. Post-mictional residue between groups

    ml, measured with BladderScan

    Time frame: Start of first intervention phase (Day 0)

  6. Post-mictional residue between groups

    ml, measured with BladderScan

    Time frame: End of first intervention phase (Day 30)

  7. Post-mictional residue between groups

    ml, measured with BladderScan

    Time frame: Start of first intervention phase (Day 60)

  8. Post-mictional residue between groups

    ml, measured with BladderScan

    Time frame: End of first intervention phase (Day 90)

  9. Maximum urine flow rate between groups

    ml/s

    Time frame: Start of first intervention phase (Day 0)

  10. Maximum urine flow rate between groups

    ml/s

    Time frame: End of first intervention phase (Day 30)

  11. Maximum urine flow rate between groups

    ml/s

    Time frame: Start of first intervention phase (Day 60)

  12. Maximum urine flow rate between groups

    ml/s

    Time frame: End of first intervention phase (Day 90)

  13. Quality of life linked to urinary dysfunction between groups

    Qualiveen-30 questionnaire; score 0-4

    Time frame: Start of first intervention phase (Day 0)

  14. Quality of life linked to urinary dysfunction between groups

    Qualiveen-30 questionnaire; score 0-4

    Time frame: End of first intervention phase (Day 30)

  15. Quality of life linked to urinary dysfunction between groups

    Qualiveen-30 questionnaire; score 0-4

    Time frame: Start of first intervention phase (Day 60)

  16. Quality of life linked to urinary dysfunction between groups

    Qualiveen-30 questionnaire; score 0-4

    Time frame: End of first intervention phase (Day 90)

  17. Quality of life between groups

    EQ-5D questionnaire; score 0-100

    Time frame: Start of first intervention phase (Day 0)

  18. Quality of life between groups

    EQ-5D questionnaire; score 0-100

    Time frame: End of first intervention phase (Day 30)

  19. Quality of life between groups

    EQ-5D questionnaire; score 0-100

    Time frame: Start of first intervention phase (Day 60)

  20. Quality of life between groups

    EQ-5D questionnaire; score 0-100

    Time frame: End of first intervention phase (Day 90)

  21. Fatigue between groups

    Modified Fatigue Impact Scale; score 0-84

    Time frame: Start of first intervention phase (Day 0)

  22. Fatigue between groups

    Modified Fatigue Impact Scale; score 0-84

    Time frame: End of first intervention phase (Day 30)

  23. Fatigue between groups

    Modified Fatigue Impact Scale; score 0-84

    Time frame: Start of first intervention phase (Day 60)

  24. Fatigue between groups

    Modified Fatigue Impact Scale; score 0-84

    Time frame: End of first intervention phase (Day 90)

  25. Drug safety

    Yes/no occurence of the following adverse events: headache, asthenia, gastrointestinal disorders, orthostatic hypotension

    Time frame: End of first intervention phase (Day 30)

  26. Drug safety

    Yes/no occurence of the following adverse events: headache, asthenia, gastrointestinal disorders, orthostatic hypotension

    Time frame: End of first intervention phase (Day 90)

07

Study locations

1 of 1 sites recruiting
  • CHU de Nîmes
    Nîmes, France
    Recruiting
    • Anissa Megzari · Contactdrc@chu-nimes.fr · 04.66.68.42.36
    • Eric Thouvenot · Sub investigator
    • Giovanni Castelnovo · Sub investigator
    • Stéphane Droupy · Principal investigator
    • Kamel Ben Naoum · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Mar 2026, 41 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 41 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2022
First posted
Jun 30, 2022
StartActual
Oct 5, 2022
Primary completionEst.
Mar 2026
CompletionEst.
Mar 2026
Last update
Jun 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05439902
Responsible party
Sponsor
First posted
Jun 30, 2022
Start date
Oct 5, 2022
Primary completion
Mar 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Jun 25, 2024

Study contacts

Stéphane DROUPY
Contact
stephane.droupy@chu-nimes.fr
04.66.68.32.30
Stéphane DROUPY
principal investigator · CHU de Nimes

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion